Brief: Aprea Unveils Initial Clinical Data On ATRi, ATRN-119, And Pre-Clinical Data On WEE1i, ATRN-1051
Oct 16 (Reuters) - Aprea Therapeutics Inc APRE.O :
* APREA UNVEILS INITIAL CLINICAL DATA ON ATRI, ATRN-119, AND
PRE-CLINICAL DATA ON WEE1I, ATRN-1051, AT AACR-NCI-EORTC
INTERNATIONAL CONFERENCE SUPPORTING HIGHLY DIFFERENTIATED
SYNTHETIC LETHALITY PORTFOLIO
Source text for Eikon: ID:nGNX3j7ZXk
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing